This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, New York
  2. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York
  3. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
  4. Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, New York
  5. Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, New York
  6. Center for Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey
  7. Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey
  8. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
  9. Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, New York
  10. Corresponding author: Renee D. Goodwin, PhD, MPH, Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, 55 West 125th Street, New York, NY 10027 ([email protected]).
  1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70. PubMed CrossRef
  2. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564–1574. PubMed CrossRef
  3. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. SAMHSA website. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf.
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition (DSM-V). Washington, DC: American Psychiatric Association; 2013.
  5. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72(12):1235–1242. PubMed CrossRef
  6. Hasin DS, Shmulewitz D, Sarvet AL. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. Am J Drug Alcohol Abuse. 2019;45(6):623–643. PubMed CrossRef
  7. Grucza RA, Agrawal A, Krauss MJ, et al. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry. 2016;73(3):300–301. PubMed CrossRef
  8. Santaella-Tenorio J, Levy NS, Segura LE, et al. Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016. Drug Alcohol Depend. 2019;205:107621. PubMed CrossRef
  9. Campbell CI, Bahorik AL, Kline-Simon AH, et al. The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. Drug Alcohol Depend. 2017;178:170–175. PubMed CrossRef
  10. Compton WM, Gfroerer J, Conway KP, et al. Unemployment and substance outcomes in the United States 2002–2010. Drug Alcohol Depend. 2014;142:350–353. PubMed CrossRef
  11. Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–297. PubMed CrossRef
  12. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328. PubMed CrossRef
  13. Ecker AH, Lang B, Hogan J, et al. Cannabis use disorder among veterans: comorbidity and mental health treatment utilization. J Subst Abuse Treat. 2020;109:46–49. PubMed CrossRef
  14. Flórez-Salamanca L, Secades-Villa R, Budney AJ, et al. Probability and predictors of cannabis use disorders relapse: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2013;132(1–2):127–133. PubMed CrossRef
  15. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction. 2012;107(7):1221–1233. PubMed CrossRef
  16. Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict. 2015;24(2):105–116. PubMed CrossRef
  17. Goodwin RD, Pacek LR, Copeland J, et al. Trends in daily cannabis use among cigarette smokers: United States, 2002–2014. Am J Public Health. 2018;108(1):137–142. PubMed CrossRef
  18. Weinberger AH, Pacek LR, Wall MM, et al. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002–2016. Drug Alcohol Depend. 2018;191:45–51. PubMed CrossRef
  19. US Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
  20. GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885–1906. PubMed CrossRef
  21. Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction. 2012;107(8):1404–1417. PubMed CrossRef
  22. Subramaniam P, McGlade E, Yurgelun-Todd D. Comorbid cannabis and tobacco use in adolescents and adults. Curr Addict Rep. 2016;3(2):182–188. PubMed CrossRef
  23. Meier E, Hatsukami DK. A review of the additive health risk of cannabis and tobacco co-use. Drug Alcohol Depend. 2016;166:6–12. PubMed CrossRef
  24. Agrawal A, Lynskey MT, Madden PA, et al. Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women. Drug Alcohol Depend. 2009;101(1-2):8–12. PubMed CrossRef
  25. Hindocha C, Shaban ND, Freeman TP, et al. Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom. Drug Alcohol Depend. 2015;148:165–171. PubMed CrossRef
  26. Montgomery L. Marijuana and tobacco use and co-use among African Americans: results from the 2013, National Survey on Drug Use and Health. Addict Behav. 2015;51:18–23. PubMed CrossRef
  27. Behrendt S, Beesdo-Baum K, Höfler M, et al. The relevance of age at first alcohol and nicotine use for initiation of cannabis use and progression to cannabis use disorders. Drug Alcohol Depend. 2012;123(1-3):48–56. PubMed CrossRef
  28. Lewinsohn PM, Rohde P, Brown RA. Level of current and past adolescent cigarette smoking as predictors of future substance use disorders in young adulthood. Addiction. 1999;94(6):913–921. PubMed CrossRef
  29. Dierker L, Braymiller J, Rose J, et al. Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults. Drug Alcohol Depend. 2018;187:212–220. PubMed CrossRef
  30. Fairman BJ, Furr-Holden CD, Johnson RM. When marijuana is used before cigarettes or alcohol: demographic predictors and associations with heavy use, cannabis use disorder, and other drug-related outcomes. Prev Sci. 2019;20(2):225–233. PubMed CrossRef
  31. Maxwell JC, Mendelson B. What do we know now about the impact of the laws related to marijuana? J Addict Med. 2016;10(1):3–12. PubMed CrossRef
  32. Shi Y, Lenzi M, An R. Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries. PLoS One. 2015;10(11):e0143562. PubMed CrossRef
  33. Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195–212. PubMed CrossRef
  34. Grant BF, Moore TC, Shepard J, et al. Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2003.
  35. Grant BF, Kaplan KD. Source and Accuracy Statement: The Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 2005.
  36. Grant BF, Dawson DA, Hasin DS. The Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV Version. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2001.
  37. Grant BF, Harford TC, Dawson DA, et al. The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend. 1995;39(1):37–44. PubMed CrossRef
  38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
  39. Creamer MR, Wang TW, Babb S, et al. Tobacco product use and cessation indicators among adults - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(45):1013–1019. PubMed CrossRef
  40. Weinberger AH, Funk AP, Goodwin RD. A review of epidemiologic research on smoking behavior among persons with alcohol and illicit substance use disorders. Prev Med. 2016;92:148–159. PubMed CrossRef
  41. Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the US population. Tob Control. 2014;23(e2):e147–e153. PubMed CrossRef
  42. Hines LA, Morley KI, Strang J, et al. Onset of opportunity to use cannabis and progression from opportunity to dependence: are influences consistent across transitions? Drug Alcohol Depend. 2016;160:57–64. PubMed CrossRef
  43. van der Pol P, Liebregts N, de Graaf R, et al. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug Alcohol Depend. 2013;133(2):352–359. PubMed CrossRef
  44. Butterworth P, Slade T, Degenhardt L. Factors associated with the timing and onset of cannabis use and cannabis use disorder: results from the 2007 Australian National Survey of Mental Health and Well-Being. Drug Alcohol Rev. 2014;33(5):555–564. PubMed CrossRef
  45. Braveman PA, Egerter SA, Mockenhaupt RE. Broadening the focus: the need to address the social determinants of health. Am J Prev Med. 2011;40(suppl 1):S4–S18. PubMed CrossRef
  46. Lemyre A, Poliakova N, Bélanger RE. The relationship between tobacco and cannabis use: a review. Subst Use Misuse. 2019;54(1):130–145. PubMed CrossRef
  47. Schauer GL, Rosenberry ZR, Peters EN. Marijuana and tobacco co-administration in blunts, spliffs, and mulled cigarettes: a systematic literature review. Addict Behav. 2017;64:200–211. PubMed CrossRef
  48. Ream GL, Benoit E, Johnson BD, et al. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend. 2008;95(3):199–208. PubMed CrossRef
  49. Fairman BJ. Cannabis problem experiences among users of the tobacco-cannabis combination known as blunts. Drug Alcohol Depend. 2015;150:77–84. PubMed CrossRef
  50. Giroud C, de Cesare M, Berthet A, et al. E-Cigarettes: a review of new trends in cannabis use. Int J Environ Res Public Health. 2015;12(8):9988–10008. PubMed CrossRef
  51. Haney M, Bedi G, Cooper ZD, et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry. 2013;73(3):242–248. PubMed CrossRef
  52. Hill KP, Toto LH, Lukas SE, et al. Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: a pilot study. Am J Addict. 2013;22(3):233–238. PubMed CrossRef
  53. Lee DC, Budney AJ, Brunette MF, et al. Treatment models for targeting tobacco use during treatment for cannabis use disorder: case series. Addict Behav. 2014;39(8):1224–1230. PubMed CrossRef
  54. Lee DC, Budney AJ, Brunette MF, et al. Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use. Drug Alcohol Depend. 2015;155:134–140. PubMed CrossRef
  55. Lee DC, Walker DD, Hughes JR, et al. Sequential and simultaneous treatment approaches to cannabis use disorder and tobacco use. J Subst Abuse Treat. 2019;98:39–46. PubMed CrossRef
  56. Becker J, Haug S, Kraemer T, et al. Feasibility of a group cessation program for co-smokers of cannabis and tobacco. Drug Alcohol Rev. 2015;34(4):418–426. PubMed CrossRef
  57. Becker J, Haug S, Sullivan R, et al. Effectiveness of different Web-based interventions to prepare co-smokers of cigarettes and cannabis for double cessation: a three-arm randomized controlled trial. J Med Internet Res. 2014;16(12):e273. PubMed CrossRef
  58. Becker J, Hungerbuehler I, Berg O, et al. Development of an integrative cessation program for co-smokers of cigarettes and cannabis: demand analysis, program description, and acceptability. Subst Abuse Treat Prev Policy. 2013;8(1):33. PubMed CrossRef
  59. Connor Gorber S, Schofield-Hurwitz S, Hardt J, et al. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res. 2009;11(1):12–24. PubMed CrossRef
  60. Fendrich M, Johnson TP, Wislar JS, et al. The utility of drug testing in epidemiological research: results from a general population survey. Addiction. 2004;99(2):197–208. PubMed CrossRef
  61. US Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2016.
  62. Tucker JS, Pedersen ER, Seelam R, et al. Types of cannabis and tobacco/nicotine co-use and associated outcomes in young adulthood. Psychol Addict Behav. 2019;33(4):401–411. PubMed CrossRef
  63. Zhu SH, Sun JY, Bonnevie E, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23(suppl 3):iii3–iii9. PubMed CrossRef
  64. Connolly GN, Alpert HR, Wayne GF, et al. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997–2005. Tob Control. 2007;16(5):e5. PubMed CrossRef
  65. Land T, Keithly L, Kane K, et al. Recent increases in efficiency in cigarette nicotine delivery: implications for tobacco control. Nicotine Tob Res. 2014;16(6):753–758. PubMed CrossRef
  66. Freeman TP, Craft S, Wilson J, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116(5):1000–1010 PubMed
  67. Arterberry BJ, Treloar Padovano H, Foster KT, et al. Higher average potency across the United States is associated with progression to first cannabis use disorder symptom. Drug Alcohol Depend. 2019;195:186–192. PubMed CrossRef
  68. Schoenborn CA, Adams PF, Peregoy JA. Health behaviors of adults: United States, 2008–2010. Vital Health Stat 10. 2013;10(257):1–184. PubMed
  69. Lantz PM. Smoking on the rise among young adults: implications for research and policy. Tob Control. 2003;12(suppl 1):i60–i70. PubMed CrossRef